

NASPGHAN Foundation/AstraZeneca Research Award for Disorders of the Upper Gastrointestinal Tract

Submission Deadline: July 1, 2024

Description and Objective

This award will provide \$75,000 annually for two years (total \$150,000) for studies focused on the epidemiology, pathogenesis, natural history, genetics, diagnosis and management of diseases of the upper gastrointestinal tract in children. Diseases that are relevant to this announcement include, but **are not limited to**:

- Gastroesophageal reflux
- Reflux esophagitis
- Celiac disease
- Eosinophilic (allergic) esophagitis/gastritis/duodenitis
- Motility disorders of the esophagus/stomach/duodenum
- Helicobacter pylori infection with or without ulceration
- Functional nausea/dyspepsia/vomiting
- Non-bacterial ulcer diseases.
- Achalasia
- Hiatal hernia

Investigators at any career level may apply.

Eligibility

- The principal investigator must be a member in good standing of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition for at least two years at the time of the application. Inclusion of co-investigators or collaborators in other scientific disciplines is encouraged.
- Applicants must hold a faculty position at a North American University or research institute and hold an MD, DO, PhD, MD/PhD or equivalent degree.
- The applicant may not hold funding from any granting agency for a project that has an overlapping scientific objective at the time of the award is made or during the two year period of the award
- Applicant must not hold another NASPGHAN Foundation grant at the start of the award (Mid-December 2024).
- Applications in either the clinical, translational or laboratory sciences are eligible.

Grant Term and Stipulations

- The award is \$75,000 in direct costs per year for up to two years of support.
- Institutional indirect costs are not permitted.
- All publications resulting from work supported by the NASPGHAN Foundation must acknowledge support by the relevant funding mechanism.
- A complete financial statement and scientific progress report are required annually. The recipient will be
 required to indicate how the funds were used; the accomplishments achieved during the project and how
 the additional training contributed to his/her research career development.
- The awardee must attend the 2024 NASPGHAN Annual Meeting to accept the award. The awardee must present the results of the research project at the 2026 NASPGHAN Annual Meeting.
- Funds for grants awarded in 2024 will be disbursed in mid-December 2024.

Review Procedures

The NASPGHAN Research Committee and invited ad hoc experts (as invited by the Research Committee Study

Section Chair) will review the applications and score proposals using the National Institutes of Health scoring system. This scoring system uses a 9-point scale for the overall impact score and individual scores for (at least) five scored criteria (significance, innovation, approach, investigators, and environment).

Projects should test novel and significant hypotheses that, if confirmed, will have substantial impact on the field of pediatric gastroenterology, hepatology, or nutrition. Applications from a broad range of inquiry are encouraged. Examples include but are not limited to: new model systems, discovery of drugs or other therapeutic agents, innovative clinical techniques or methodologies, biomedical engineering and computational biology, translational diagnostic or therapeutic advances, cell biology and molecular genetics.

Members of the review panel will follow strict conflict of interest guidelines. Contact between the applicant or sponsors with committee members regarding applications is strictly prohibited and will lead to potential disqualification.



NASPGHAN FOUNDATION/AstraZeneca Research Award for Disorders of the Upper Gastrointestinal Tract

APPLICATION INSTRUCTIONS:

FAILURE TO ADHERE STRICTLY TO THESE GUIDELINES COULD RESULT IN THE DISQUALIFICATION OF YOUR APPLICATION

Completed applications must include the following.

- 1. A biographical sketch in the most recent NIH format for the PI and all key personnel (https://grants.nih.gov/grants/forms/biosketch.htm). The biosketch should list specific aims of all active research funding to permit an assessment of scientific overlap with the investigator's existing extramural funding.
- 2. The research plan structured according to the NIH format as outlined below with 1/2-inch margins. Times New Roman or Arial font no less than 11 point are required. Page limitations and style requirements are strictly enforced. (No research plan more than SEVEN single spaced pages will be reviewed. References and additional criteria are not included in this maximum page count).
 - Scientific Abstract (1 page) suitable for use in the public domain should succinctly describe the scope of the proposed research, the study hypothesis, its scientific objectives, and the potential for innovation. Relevance of the proposed research to pediatric gastroenterology, hepatology and nutrition should be emphasized. The names and institutional affiliations of the principal investigator and all co- investigators should be tabulated at the end of this page.
 - Specific aims (1 page):
 - * Explain the rationale for the study, overall hypothesis, aims, and significance if successful.
 - Research Strategy (4 pages) including Significance, Innovation, and Approach
 - a. Significance
 - * Explain the importance of the problem or critical barrier to progress in the field that the proposed project addresses.
 - Explainhowthe proposed project will improve scientificknowledge, technical capability, and/or clinical practice in one or more broad fields.
 - * Describe how the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field will be changed if the proposed aims are achieved.

b. Innovation

- * Explain how the application challenges and seeks to shift current research or clinical practice paradigms.
- * Describe any novel theoretical concepts, approaches or methodologies, instrumentation or interventions to be developed or used, and any advantage over existing methodologies, instrumentation, or interventions.
- * Explain any refinements, improvements, or new applications of theoretical concepts, approaches or methodologies, instrumentation, or interventions.

c. Approach

- * Provide preliminary data (strongly preferred but not required) that supports the premise for the work.
- * Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project. Include how the data will be collected, analyzed including statistical plan, and interpreted as well as any resource sharing plans as appropriate.
- * Discuss expected results, potential problems, alternative strategies, feasibility, timeline, and benchmarks for success anticipated to achieve the aims. A power calculation is encouraged where

- relevant to underscore feasibility.
- * If the project is in the early stages of development, describe strategies both to enhance feasibility and address the management of any high-risk aspects of the proposed work.
- 3. The research plan structured according to the NIH format as outlined below with 1/2-inch margins. Times New Roman or Arial font no less than 11 point are required. Page limitations and style requirements are strictly enforced. (No research plan more than SEVEN single spaced pages will be reviewed. References and additional criteria are not included in this maximum page count).
 - * Laboratory
 - * Clinical
 - * Animal
 - * Computer

- * Office
- * Major Equipment
- * Other Resources

References (Not counted towards page limits)

- 4. Additional criteria (1 page limit):
 - Human subjects research: For studies involving human subjects, explain whether there is an existing IRBapproved protocol in place. If not, please outline your plans to obtain IRB approval, or explain why your protocol may not require this.
 - Animal studies: For studies involving animals, explain whether an animal protocol is approved or planned.
 - Inclusion plans: NASPGHAN is committed to decreasing disparities in patient care and outcomes and one way is through actively considering health equity in research study design.
 - **a. For patient-oriented and other human subjects research**, include the following: Inclusion Across the Lifespan: Include a brief description of the scientific rationale and plan for the age of participants included in the proposal.
 - * Health Equity Research: Include a brief description of the scientific rationale and plan for inclusion of underserved groups.
 - * Describe the composition of the proposed study population in terms of sex/gender and racial/ethnic group, and provide a rational for selection of such study subjects.
 - * As appropriate, please describe specific efforts undertaken by the program including outreach strategies and activities designed to recruit prospective participants from diverse groups.

b. For research that does not involve human subjects:

If the study does not involve patient recruitment or samples, document if the research planned would have any impact in addressing disparities in care or health outcomes (directly or indirectly).

- Safety: Describe any procedures, situations, or materials that may be hazardous to personnel and precautions to be exercised.
- 5. A two-year detailed budget must be accompanied by a justification. Salary, equipment, supplies and reasonable travel costs may be budgeted. In accordance with the National Institutes of Health (NIH) policy, salary requests may not use an institutional base salary in excess of the current federal salary cap at the time of submission (https://grants.nih.gov/grants/policy/salcap_summary.htm). Fringe benefits may be requested if they are treated consistently by the applicant institution as a direct cost to all funding agencies and foundations. *Indirect costs are not allowed*.
- 6. Articles in press not available online can be included as an appendix but should only be included if material is directly relevant to the proposal. Additional articles, such as those already published or in preparation and any other additional documents, should not be included and may detract from the application.